Axatilimab has demonstrated safety, tolerability and efficacy in clinical trials; however, many questions remain unanswered including long-term safety data, efficacy when compared to other cGVHD therapies, risks and benefits of axatilimab in combination, and role in earlier lines of cGVHD treatment.
Chhabra et al. (Thu,) studied this question.